Tysabri and PML: Understanding the Statute of Limitations in Arizona

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risks

The legacy of general health and science information has long provided a foundation for public understanding of medical risks and treatment options. Within this broad context, the focus on pharmaceutical safety and patient outcomes has become increasingly prominent, particularly as therapies evolve to address complex conditions. One such therapy, Tysabri, has been associated with a rare but serious risk of progressive multifocal leukoencephalopathy (PML), a condition that has led to legal settlements and ongoing scrutiny. In Arizona, the statute of limitations for claims related to Tysabri exposure is a critical consideration for individuals who may have been affected. This transition from general health awareness to specific occupational exposure concerns is essential, as it highlights the need for vigilance among healthcare workers, patients, and others who may encounter the drug in clinical or manufacturing settings. The shift in focus underscores the importance of understanding not only the therapeutic benefits but also the potential liabilities and time-sensitive legal frameworks that govern such exposures. By bridging this gap, the discussion moves from broad health literacy to targeted risk management in environments where Tysabri is handled or administered.

Tysabri and PML: Medical Evidence and Risk Factors

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning further identifies three risk factors for PML development: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable but typically includes progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves its inhibition of alpha-4 integrin, which prevents lymphocyte trafficking into the central nervous system. This immunosuppressive effect allows reactivation of latent JC virus in the brain, leading to lytic infection of oligodendrocytes and subsequent demyelination. The FDA Adverse Event Reporting System (FAERS) lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and balance disorder among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While PML is a rare but devastating outcome, these reports underscore the importance of vigilant monitoring.

Legal Considerations and Settlements for Tysabri-Related PML

The adequacy of warnings regarding Tysabri and PML has been a subject of litigation. The boxed warning explicitly states that Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The TOUCH Prescribing Program mandates evaluation of patients three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have alleged that the warnings were insufficient or that the risks were not adequately communicated, leading to settlements in certain cases. For affected patients in Arizona, settlement-related considerations involve the statute of limitations for filing a claim. In Arizona, the statute of limitations for personal injury claims generally is two years from the date the injury is discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can be variable. PML typically develops after prolonged treatment, often beyond two years, but cases have been reported earlier. The latency period complicates the determination of when the injury was discoverable. Patients who received Tysabri and later developed PML must establish when they knew or should have known that their neurological symptoms were linked to the drug. This may involve reviewing medical records, MRI findings, and JC virus antibody test results. Settlements in Tysabri PML cases have been reached in multidistrict litigation and individual lawsuits. Factors influencing settlement amounts include the severity of disability, the patient's age, the duration of Tysabri use, and the presence of risk factors such as prior immunosuppressant use. In Arizona, patients who have not yet filed a claim should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances and ensure compliance with the statute of limitations. The TOUCH program's monitoring requirements may also be relevant, as failure to adhere to these protocols could affect liability. In summary, Tysabri-associated PML is a serious adverse event with well-documented risk factors and a defined clinical course. The adequacy of warnings and the timeline between exposure and harm are critical elements in settlement considerations. Patients in Arizona must be aware of the two-year statute of limitations from the date of discovery of the injury. Legal counsel should be sought promptly to preserve any potential claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Arizona?

In Arizona, the statute of limitations for personal injury claims generally is two years from the date the injury is discovered or reasonably should have been discovered. For Tysabri-related PML, this means the clock starts when the patient knew or should have known that their neurological symptoms were linked to the drug. Due to the variable latency of PML, it is crucial to consult an attorney promptly to preserve any potential claims.

What are the risk factors for developing PML while on Tysabri?

According to the prescribing information, three risk factors increase the risk of PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing Tysabri therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.